{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:03:35Z","timestamp":1779915815881,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with indolent B-cell non-Hodgkin lymphomas (B-NHLs) have an increased risk of infections which is caused by pathomechanisms of the diseases itself but also as a result of anti-tumor therapy. Especially the effects of anti-CD20 antibodies are well understood as these lead to decreased antibody production. Most studies regarding immunodeficiency in B-NHLs were conducted\u00a0with multiple myeloma and chronic lymphocytic leukemia patients. As these studies not always represent the general population we collected and analyzed real world data from patients with indolent lymphomas and a control group (CG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with B-NHLs undergoing therapy or who were regularly monitored in a watch and wait approach had, over the time of one year, an increased rate of infections compared to the CG of 145 healthy volunteers (mean: 11.66 vs. 7.13 infections per 1000\u00a0days). Consistent with this finding B-NHL patients received more antibiotic treatment (mean: 11.17 vs. 6.27\u00a0days) and were more often hospitalized than persons from the CG (mean: 5.19 vs. 0.99\u00a0days per 1000\u00a0days). Lymphoma patients without immunodeficiency had a lower infection rate than patients with non-symptomatic and symptomatic immunodeficiency (mean: 10.91 vs. 12.07 and 12.36 per 1000\u00a0days). The number of infections differed statistically significant for the subgroups and CG (7.13 per 1000\u00a0days). Patients with symptomatic immunodeficiency were mostly treated with regular immunoglobulin substitutions and infection rates were comparable to those of patients with asymptomatic immunodeficiency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest the use of an approach with regular immune monitoring including the measurement of immunoglobulin levels and regular appointments for clinical assessment of all indolent lymphoma patients in order to identify patients with increased risk of infections. It also raises the question if patients with immunodeficiency should be treated more often with regular immunoglobulin substitution, but so far more studies are necessary to answer this question.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12865-022-00536-x","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T13:03:07Z","timestamp":1673442187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic"],"prefix":"10.1186","volume":"24","author":[{"given":"Christoph","family":"Lutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Feiten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geothy","family":"Chakupurakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Heymanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Thomalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"van Roye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Weide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"536_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/bmb\/ldn034","volume":"87","author":"AD Hamblin","year":"2008","unstructured":"Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull. 2008;87:49\u201362.","journal-title":"Br Med Bull"},{"issue":"1","key":"536_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.13532","volume":"171","author":"BW Teh","year":"2015","unstructured":"Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171(1):100\u20138.","journal-title":"Br J Haematol"},{"issue":"6","key":"536_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","volume":"16","author":"S Srivastava","year":"2016","unstructured":"Srivastava S, Wood P. Secondary antibody deficiency\u2014causes and approach to diagnosis. Clin Med (Lond). 2016;16(6):571\u20136.","journal-title":"Clin Med (Lond)"},{"issue":"5","key":"536_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10875-007-9103-1","volume":"27","author":"JM Boyle","year":"2007","unstructured":"Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497\u2013502.","journal-title":"J Clin Immunol"},{"issue":"3","key":"536_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hon.2323","volume":"34","author":"V Friman","year":"2016","unstructured":"Friman V, Winqvist O, Blimark C, Langerbeins P, Chapel H, Dhalla F. Secondary immunodeficiency in lymphoproliferative malignancies. Hematol Oncol. 2016;34(3):121\u201332.","journal-title":"Hematol Oncol"},{"issue":"3","key":"536_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","volume":"34","author":"F Dhalla","year":"2014","unstructured":"Dhalla F, Lucas M, Schuh A, Bhole M, Jain R, Patel SY, et al. Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin? J Clin Immunol. 2014;34(3):277\u201382.","journal-title":"J Clin Immunol"},{"issue":"3","key":"536_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1182\/blood.V57.3.418.418","volume":"57","author":"NE Kay","year":"1981","unstructured":"Kay NE. Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood. 1981;57(3):418\u201320.","journal-title":"Blood"},{"issue":"10","key":"536_CR8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.4065\/75.10.1039","volume":"75","author":"S Tsiodras","year":"2000","unstructured":"Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc. 2000;75(10):1039\u201354.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"536_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228\u201337.","journal-title":"Cancer"},{"issue":"6","key":"536_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMra0708875","volume":"359","author":"BD Cheson","year":"2008","unstructured":"Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma. N Engl J Med. 2008;359(6):613\u201326.","journal-title":"N Engl J Med"},{"issue":"10","key":"536_CR11","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Foa R, Maurer J, O\u2019Brien S, Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232\u201373.","journal-title":"Adv Ther"},{"issue":"Suppl 2","key":"536_CR12","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"L Drgona","year":"2018","unstructured":"Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018;24(Suppl 2):S83\u201394.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"536_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","volume":"107","author":"M Makatsori","year":"2014","unstructured":"Makatsori M, Kiani-Alikhan S, Manson AL, Verma N, Leandro M, Gurugama NP, et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM. 2014;107(10):821\u20138.","journal-title":"QJM"},{"issue":"2","key":"536_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","volume":"13","author":"C Casulo","year":"2013","unstructured":"Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106\u201311.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"536_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2005.05.282","volume":"23","author":"SA Miles","year":"2005","unstructured":"Miles SA, McGratten M. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol. 2005;23(1):247\u20138.","journal-title":"J Clin Oncol"},{"issue":"13","key":"536_CR16","first-page":"1278","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, O\u2019Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(13):1278\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"536_CR17","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.4049\/jimmunol.1401550","volume":"193","author":"J Golay","year":"2014","unstructured":"Golay J, D\u2019Amico A, Borleri G, Bonzi M, Valgardsdottir R, Alzani R, et al. A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy. J Immunol. 2014;193(9):4739\u201347.","journal-title":"J Immunol"},{"issue":"7","key":"536_CR18","first-page":"483","volume":"39","author":"S Parmar","year":"2014","unstructured":"Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. Pharm Ther. 2014;39(7):483\u2013519.","journal-title":"Pharm Ther"},{"issue":"2","key":"536_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/cei.13012","volume":"190","author":"S Jolles","year":"2017","unstructured":"Jolles S, Sanchez-Ramon S, Quinti I, Soler-Palacin P, Agostini C, Florkin B, et al. Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. Clin Exp Immunol. 2017;190(2):226\u201334.","journal-title":"Clin Exp Immunol"},{"key":"536_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","volume":"10","author":"SY Patel","year":"2019","unstructured":"Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33.","journal-title":"Front Immunol"},{"issue":"9842","key":"536_CR21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","volume":"380","author":"C Wong","year":"2012","unstructured":"Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660\u20137.","journal-title":"Lancet"},{"issue":"11","key":"536_CR22","doi-asserted-by":"publisher","first-page":"e499","DOI":"10.1038\/bcj.2016.105","volume":"6","author":"C da Cunha-Bang","year":"2016","unstructured":"da Cunha-Bang C, Simonsen J, Rostgaard K, Geisler C, Hjalgrim H, Niemann CU. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer J. 2016;6(11):e499.","journal-title":"Blood Cancer J"},{"key":"536_CR23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","volume":"5","author":"N Compagno","year":"2014","unstructured":"Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626.","journal-title":"Front Immunol"},{"issue":"2","key":"536_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/ejh.12900","volume":"99","author":"M Reiser","year":"2017","unstructured":"Reiser M, Borte M, Huscher D, Baumann U, Pittrow D, Sommer C, et al. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study. Eur J Haematol. 2017;99(2):169\u201377.","journal-title":"Eur J Haematol"},{"issue":"2","key":"536_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-0609.1994.tb01874.x","volume":"53","author":"J Jurlander","year":"1994","unstructured":"Jurlander J, Geisler CH, Hansen MM. Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol. 1994;53(2):114\u20138.","journal-title":"Eur J Haematol"},{"issue":"6","key":"536_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1159\/000227231","volume":"50","author":"I Sklenar","year":"1993","unstructured":"Sklenar I, Schiffman G, Jonsson V, Verhoef G, Birgens H, Boogaerts M, et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Oncology. 1993;50(6):466\u201377.","journal-title":"Oncology"},{"issue":"8905","key":"536_CR27","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","volume":"343","author":"HM Chapel","year":"1994","unstructured":"Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK group for immunoglobulin replacement therapy in multiple myeloma. Lancet. 1994;343(8905):1059\u201363.","journal-title":"Lancet"},{"key":"536_CR28","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00761-017-0292-9","volume":"23","author":"R Weide","year":"2017","unstructured":"Weide R. Versorgungsforschung in der onkologischen Schwerpunktpraxen in Deutschland. Onkologe. 2017;23:911\u20137.","journal-title":"Onkologe"},{"issue":"2","key":"536_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00761-011-2200-z","volume":"18","author":"G Glaeske","year":"2012","unstructured":"Glaeske G. Spektrum der Versorgungsforschung in der Onkologie. Onkologie. 2012;18(2):105\u201315.","journal-title":"Onkologie"},{"issue":"6","key":"536_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00063-010-1073-z","volume":"105","author":"FG Hoffmann","year":"2010","unstructured":"Hoffmann FG, Glaeske G. Versorgungsforschung mit Routinedaten in der Onkologie. Med Klin (Munich). 2010;105(6):409\u201315.","journal-title":"Med Klin (Munich)"},{"key":"536_CR31","unstructured":"Parry H.M. BJ, Hudson C., DraysonM., Moss P., Pratt G., McSkeane T., Hazlewood P., Murray J., Richter A. In patients with chronic lymphocytic leukaemiaan IgG<6 g\/l correlates with infection risk andpoor functional antibody levels. British Journal of Haematology. 2014;165(s1):48\u20139."},{"issue":"2","key":"536_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175\u201391.","journal-title":"Behav Res Methods"},{"issue":"6","key":"536_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.arcmed.2015.07.004","volume":"46","author":"JC Jaime-Perez","year":"2015","unstructured":"Jaime-Perez JC, Gamboa-Alonso CM, Vazquez-Mellado de Larracoechea A, Rodriguez-Martinez M, Gutierrez-Aguirre CH, Marfil-Rivera LJ, et al. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma. Arch Med Res. 2015;46(6):454\u201361.","journal-title":"Arch Med Res"},{"issue":"4","key":"536_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2217\/imt-2021-0313","volume":"14","author":"RH Kobayashi","year":"2022","unstructured":"Kobayashi RH, Litzman J, Rizvi S, Kreuwel H, Hoeller S, Gupta S. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases. Immunotherapy. 2022;14(4):259\u201370.","journal-title":"Immunotherapy"},{"issue":"6","key":"536_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.5501\/wjv.v10.i6.312","volume":"10","author":"V Bonuomo","year":"2021","unstructured":"Bonuomo V, Ferrarini I, Dell\u2019Eva M, Sbisa E, Krampera M, Visco C. COVID-19 (SARS-CoV-2 infection) in lymphoma patients: a review. World J Virol. 2021;10(6):312\u201325.","journal-title":"World J Virol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-022-00536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-022-00536-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-022-00536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T13:03:32Z","timestamp":1673442212000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-022-00536-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1186\/s12865-022-00536-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1381867\/v1","asserted-by":"object"}]},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"21 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Rhineland-Palatinate, Germany (837.498.16 (10816)).Written informed consent was obtained from all patients. All procedures performed in this study were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}